{"title":"Quercetin ameliorates chronic restraint stress- and LPS-induced anxiety-like behaviors by modulating neuroinflammation in the lateral hypothalamus.","authors":"Xinxin Wang, Guangdong Weng, Yunpei Gao, Yu Wang, Chengxin Zhang","doi":"10.1007/s00213-025-06784-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Quercetin is a natural flavonoid which has been shown to exhibit anti-inflammatory and anxiolytic properties. Neuroinflammation has recently been identified as a major cause of anxiety disorders. Both the lateral hypothalamus (LH) and bed nucleus of the stria terminalis (BNST) are important brain regions that regulate anxiety. This study aims to explore the effect of quercetin on anxiety-like behaviors, as well as the underlying mechanisms associated with neuroinflammation in the LH and BNST.</p><p><strong>Methods: </strong>The anxiety models were established in male mice by chronic restraint stress (CRS) and lipopolysaccharide (LPS) administration. The elevated plus maze (EPM) and open field (OF) tests were used to evaluate anxiety level. Immunofluorescent staining and quantitative real-time PCR were performed to examine the expression of microglia and inflammatory cytokines in the LH and BNST of male mice.</p><p><strong>Results: </strong>Behavioral data showed that quercetin treatment in male mice significantly alleviated anxiety in the EPM and OF tests. Examination of the inflammation level further revealed that quercetin administration significantly inhibited microglia activation in the LH and BNST of CRS- and LPS-treated male mice, while concurrently reducing the levels of the pro-inflammatory cytokine interleukin-6 (IL-6) in the LH of CRS-treated male mice, as well as interleukin-1β (IL-1β) mRNA expression in the LH of LPS-treated male mice. Furthermore, we found that the expression of NF-κB was downregulated by quercetin in the LH of CRS-treated male mice.</p><p><strong>Conclusion: </strong>Our study indicates the clinical potential of quercetin in neuroinflammation-related anxiety, and begins to show that the underlying mechanism in the chronic restraint stress condition may potentially involve the modulation of NF‑κB signaling pathway in the LH.</p>","PeriodicalId":20783,"journal":{"name":"Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00213-025-06784-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: Quercetin is a natural flavonoid which has been shown to exhibit anti-inflammatory and anxiolytic properties. Neuroinflammation has recently been identified as a major cause of anxiety disorders. Both the lateral hypothalamus (LH) and bed nucleus of the stria terminalis (BNST) are important brain regions that regulate anxiety. This study aims to explore the effect of quercetin on anxiety-like behaviors, as well as the underlying mechanisms associated with neuroinflammation in the LH and BNST.
Methods: The anxiety models were established in male mice by chronic restraint stress (CRS) and lipopolysaccharide (LPS) administration. The elevated plus maze (EPM) and open field (OF) tests were used to evaluate anxiety level. Immunofluorescent staining and quantitative real-time PCR were performed to examine the expression of microglia and inflammatory cytokines in the LH and BNST of male mice.
Results: Behavioral data showed that quercetin treatment in male mice significantly alleviated anxiety in the EPM and OF tests. Examination of the inflammation level further revealed that quercetin administration significantly inhibited microglia activation in the LH and BNST of CRS- and LPS-treated male mice, while concurrently reducing the levels of the pro-inflammatory cytokine interleukin-6 (IL-6) in the LH of CRS-treated male mice, as well as interleukin-1β (IL-1β) mRNA expression in the LH of LPS-treated male mice. Furthermore, we found that the expression of NF-κB was downregulated by quercetin in the LH of CRS-treated male mice.
Conclusion: Our study indicates the clinical potential of quercetin in neuroinflammation-related anxiety, and begins to show that the underlying mechanism in the chronic restraint stress condition may potentially involve the modulation of NF‑κB signaling pathway in the LH.
期刊介绍:
Official Journal of the European Behavioural Pharmacology Society (EBPS)
Psychopharmacology is an international journal that covers the broad topic of elucidating mechanisms by which drugs affect behavior. The scope of the journal encompasses the following fields:
Human Psychopharmacology: Experimental
This section includes manuscripts describing the effects of drugs on mood, behavior, cognition and physiology in humans. The journal encourages submissions that involve brain imaging, genetics, neuroendocrinology, and developmental topics. Usually manuscripts in this section describe studies conducted under controlled conditions, but occasionally descriptive or observational studies are also considered.
Human Psychopharmacology: Clinical and Translational
This section comprises studies addressing the broad intersection of drugs and psychiatric illness. This includes not only clinical trials and studies of drug usage and metabolism, drug surveillance, and pharmacoepidemiology, but also work utilizing the entire range of clinically relevant methodologies, including neuroimaging, pharmacogenetics, cognitive science, biomarkers, and others. Work directed toward the translation of preclinical to clinical knowledge is especially encouraged. The key feature of submissions to this section is that they involve a focus on clinical aspects.
Preclinical psychopharmacology: Behavioral and Neural
This section considers reports on the effects of compounds with defined chemical structures on any aspect of behavior, in particular when correlated with neurochemical effects, in species other than humans. Manuscripts containing neuroscientific techniques in combination with behavior are welcome. We encourage reports of studies that provide insight into the mechanisms of drug action, at the behavioral and molecular levels.
Preclinical Psychopharmacology: Translational
This section considers manuscripts that enhance the confidence in a central mechanism that could be of therapeutic value for psychiatric or neurological patients, using disease-relevant preclinical models and tests, or that report on preclinical manipulations and challenges that have the potential to be translated to the clinic. Studies aiming at the refinement of preclinical models based upon clinical findings (back-translation) will also be considered. The journal particularly encourages submissions that integrate measures of target tissue exposure, activity on the molecular target and/or modulation of the targeted biochemical pathways.
Preclinical Psychopharmacology: Molecular, Genetic and Epigenetic
This section focuses on the molecular and cellular actions of neuropharmacological agents / drugs, and the identification / validation of drug targets affecting the CNS in health and disease. We particularly encourage studies that provide insight into the mechanisms of drug action at the molecular level. Manuscripts containing evidence for genetic or epigenetic effects on neurochemistry or behavior are welcome.